Mitotane (o,p′DDD) is the most effective treatment of advanced adrenocortical carcinoma (ACC) but its mechanism of action remains unknown. Previous studies suggested that o,p′DDA may represent the active metabolite of mitotane. We aimed at reevaluating the potential role and pharmacological effects of o,p′DDA. Functional consequences of o,p′DDA exposure were studied on proliferation, steroidogenesis, and mitochondrial respiratory chain in human H295R and SW13 adrenocortical cells. Mitotane and its metabolites were quantified using high-performance liquid chromatography combined to an ultraviolet detection in these cells treated with o,p′DDD or o,p′DDA and in human adrenal tissues. Dose–response curves up to 300 μM showed that, as opposed to o,p′DDD, o,p′DDA did not inhibit cell proliferation nor alter respiratory chain complex IV activity, gene expression nor induce mitochondrial biogenesis, oxidative stress, or apoptosis. However, whereas mitotane drastically decreased expression of genes involved in steroidogenesis, o,p′DDA slightly reduced expression of some steroidogenic enzymes and exerts weak anti-secretory effects only at high doses. While o,p′DDD concentration was significantly reduced by 40 % in H295R cell supernatants after 48 h incubation, o,p′DDA levels remained unchanged suggesting that o,p′DDA was not efficiently transported into the cells. o,p′DDA was not detected in cell homogenates or supernatants after 48 h exposure to o,p′DDD, consistent with the absence of o,p′DDA production in these models. Finally, unlike o′p′DDD, we found that o,p′DDA content was undetectable in two ACC and one normal adrenal gland of mitotane-treated patients, suggesting a lack of cellular uptake and in situ production. Our results demonstrate that o,p′DDD, but not o,p′DDA, induces functional alterations in adrenal cells.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
The authors are indebted to HRA Pharma for supporting this research. This work was supported by the Institut National de la Santé et de la Recherche Médicale (Inserm) and Université Paris-Sud. SH is recipient of a fellowship from HRA Pharma Laboratories (Bourse CIFRE).
Conflict of Interest
The authors declare that they have no conflict of interest.
Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667–680. doi:10.1677/erc.1.01029PubMedCrossRefGoogle Scholar
Berruti A, Baudin E, Gelderblom H et al (2012) Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO 23(Suppl 7):vii131–vii138. doi:10.1093/annonc/mds231CrossRefGoogle Scholar
Berruti A, Fassnacht M, Baudin E et al (2010) Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol Off J Am Soc Clin Oncol 28:e401–e402. doi:10.1200/JCO.2009.27.5958, author reply e403CrossRefGoogle Scholar
Else T, Williams AR, Sabolch A et al (2014) Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 99:455–461. doi:10.1210/jc.2013-2856PubMedCrossRefGoogle Scholar
Haak HR, Hermans J, van de Velde CJ et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947–951PubMedCrossRefPubMedCentralGoogle Scholar
Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385–1392PubMedCrossRefGoogle Scholar
Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma (ACC). Endocr Relat Cancer. doi:10.1677/ERC-09-0341PubMedGoogle Scholar
Wängberg B, Khorram-Manesh A, Jansson S et al (2010) The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 17:265–272. doi:10.1677/ERC-09-0190PubMedCrossRefGoogle Scholar
Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844–1851. doi:10.1210/jc.2010-2676PubMedCrossRefGoogle Scholar
Ayala-Ramirez M, Jasim S, Feng L et al (2013) Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol Eur Fed Endocr Soc 169:891–899. doi:10.1530/EJE-13-0519CrossRefGoogle Scholar
Van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47–53PubMedCrossRefGoogle Scholar
Moy RH (1961) Studies of the pharmacology of o,p’DDD in man. J Lab Clin Med 58:296–304PubMedGoogle Scholar
Sinsheimer JE, Guilford J, Bobrin LJ, Schteingart DE (1972) Identification of o,p’-dichlorodiphenyl acetic acid as a urinary metabolite of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane. J Pharm Sci 61:314–316PubMedCrossRefGoogle Scholar
Reif VD, Sinsheimer JE (1975) Metabolism of 1-(0-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p’-DDD) in rats. Drug Metab Dispos Biol Fate Chem 3:15–25PubMedGoogle Scholar
Martz F, Straw JA (1980) Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p’,-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metab Dispos Biol Fate Chem 8:127–130PubMedGoogle Scholar
Pohland RC, Counsell RE (1985) In vitro and in vivo metabolism of a radioiodinated analog of 1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,-dichloroethane. Drug Metab Dispos Biol Fate Chem 13:113–115PubMedGoogle Scholar
Martz F, Straw JA (1977) The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p’-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos Biol Fate Chem 5:482–486PubMedGoogle Scholar
Cai W, Benitez R, Counsell RE et al (1995) Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p’-DDD] and its p,p’- and m,p’-isomers. Biochem Pharmacol 49:1483–1489PubMedCrossRefGoogle Scholar
Cai W, Counsell RE, Djanegara T et al (1995) Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 84:134–138PubMedCrossRefGoogle Scholar
Cai W, Counsell RE, Schteingart DE et al (1997) Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemother Pharmacol 39:537–540PubMedCrossRefGoogle Scholar
Hescot S, Slama A, Lombès A et al (2013) Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 20:371–381. doi:10.1530/ERC-12-0368PubMedCrossRefGoogle Scholar
Mauclère-Denost S, Leboulleux S, Borget I et al (2012) High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol Eur Fed Endocr Soc 166:261–268. doi:10.1530/EJE-11-0557CrossRefGoogle Scholar
Lehmann TP, Wrzesiński T, Jagodziński PP (2013) The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells. Mol Med Rep 7:893–900. doi:10.3892/mmr.2012.1244PubMedGoogle Scholar
Poli G, Guasti D, Rapizzi E et al (2013) Morpho-functional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer. doi:10.1530/ERC-13-0150PubMedGoogle Scholar
Chortis V, Taylor AE, Schneider P et al (2013) Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 98:161–171. doi:10.1210/jc.2012-2851PubMedCrossRefGoogle Scholar
Schteingart DE, Sinsheimer JE, Benitez RS et al (2012) Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer. Anticancer Res 32:2711–2720PubMedGoogle Scholar
Asp V, Cantillana T, Bergman A, Brandt I (2010) Chiral effects in adrenocorticolytic action of o,p’-DDD (mitotane) in human adrenal cells. Xenobiotica Fate Foreign Compd Biol Syst 40:177–183. doi:10.3109/00498250903470230CrossRefGoogle Scholar